CTx-1301

CTx-1301 is a novel, investigational once-daily oral stimulant medication for the treatment of attention-deficit/hyperactivity disorder (ADHD). It is a proprietary multi-core (tri-modal) formulation of dexmethylphenidate hydrochloride designed to provide rapid onset and sustained therapeutic levels throughout the entire active day—up to 14–16 hours. The tablet contains an immediate-release layer, a delayed extended-release layer, and a final immediate-release core. This design aims to minimize rebound effects and improve tolerability by controlling the descent of drug levels. Developed using Precision Timed Release™ technology in collaboration with BDD Pharma, CTx-1301 has demonstrated statistically significant improvements in ADHD symptoms in both pediatric and adult phase 3 clinical trials. The drug is being developed by Cingulate as a potential first-line therapy for ADHD patients aged 6 years and older[1][3][5][6][7].

Brand names

CTx-1301CTx1301CTx 1301

Other names

dexmethylphenidate multi-core formulationtri-modal d-MPH tabletdexmethylphenidate HCl (CTx-1301)